Biotech | November 18, 2021
Daiichi Sankyo initiates Phase 2 trial of mRNA Covid-19 vaccine in Japan
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The cream has an estimated market size of US $ 28 million for twelve months ending Jun 2021 according to IQVIA
Launching in 2022, its availability will be expanded to the global market
The Indian Pharmacopoeia Commission (IPC) has added 23 new impurities standards and 7 new Indian Pharmacopoeial Reference standards
Vakrangee’s distribution network across rural India will help penetrate underserved markets
The group now has 324 approvals and has so far filed over 400 ANDAs
The company performed particularly well in operational eco-efficiency, environmental and social reporting
Subscribe To Our Newsletter & Stay Updated
